Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 56 peer-reviewed journal articles Updated

Understanding Eosinophilic Fasciitis (Shulman Syndrome)

At a Glance

Eosinophilic Fasciitis (Shulman Syndrome) is a rare autoimmune disorder where the immune system attacks the fascia, causing tissue beneath the skin to swell and harden. Early diagnosis with a full-thickness biopsy and prompt treatment with medications like corticosteroids can prevent joint stiffness.

If you are reading this, you may have recently heard the term Eosinophilic Fasciitis (EF)—also known as Shulman Syndrome—perhaps after weeks or months of searching for an explanation for your skin changes [1][2]. It is a rare autoimmune disorder where the body’s immune system mistakenly attacks its own connective tissue, specifically the fascia (the tough, fibrous layer of tissue that wraps around muscles, nerves, and blood vessels) [3][4].

Because EF is so rare, it is common to feel isolated or overwhelmed. Many patients face long diagnostic delays because the symptoms can look like more common skin or joint conditions [5][6]. Understanding what is happening beneath your skin is the first step in taking control of your health journey.

What is Happening to the Fascia?

In a healthy body, the fascia is flexible and allows your muscles to move smoothly. In EF, this layer becomes severely inflamed, swollen, and eventually thickens and hardens (induration) [3][7].

This process is driven by specific signals in your immune system:

  • Interleukin-6 (IL-6): A protein that acts as a “fire alarm” for the immune system, triggering widespread inflammation [8][9].
  • Transforming Growth Factor-beta (TGF-beta): A chemical messenger that tells the body to produce excess collagen. While this helps heal normal wounds, in EF, it leads to the “scar-like” hardening of the fascia [8].

As the fascia thickens, it can pull on the skin above it, creating a “groove” along the path of your veins or a texture similar to an orange peel [7][10].

Who Gets EF and Why?

EF can affect anyone at any age, including children, but it is most frequently diagnosed in adults in their 40s and 50s [2]. While the exact cause is often unknown, researchers have identified several “triggers” that may jump-start the inflammation:

  • Physical Stress: Strenuous or unusual exercise and physical trauma (like a fall or injury) are well-documented triggers [4].
  • Medications: A specific type of cancer therapy called immune checkpoint inhibitors (such as anti-PD-1 drugs) has been linked to the development of EF-like symptoms [11][12].
  • Unknown Causes: In many cases, EF is “idiopathic,” meaning it occurs without a clear external trigger.

Navigating a Rare Diagnosis

Because EF is rare, there are currently no “gold standard” international guidelines that every doctor follows [13][14]. Instead, specialists often rely on specific diagnostic frameworks like the Pinal-Fernandez or Jinnin criteria to confirm the disease [15][16].

The emotional journey of a rare disease can be taxing. You may have been told your symptoms were “just muscle strain” or “simple swelling” before receiving this diagnosis [5]. It is important to know that:

01

Managing Your Treatment: Options and Strategies for EF

Explore treatment options for Eosinophilic Fasciitis (EF). Learn about first-line therapies like corticosteroids, managing side effects, and physical therapy.

02

The Diagnostic Process: Biopsy, MRI, and Blood Tests

Learn how Eosinophilic Fasciitis (EF) is diagnosed. Understand the importance of a full-thickness biopsy, MRI scans, and blood tests in confirming EF.

Common questions in this guide

What causes Eosinophilic Fasciitis?
While the exact cause is often unknown, it can be triggered by strenuous physical exercise, injuries, or certain cancer medications called immune checkpoint inhibitors. In many cases, it occurs without any clear external trigger.
How is Eosinophilic Fasciitis diagnosed?
Diagnosing this condition requires a specialized full-thickness biopsy. This procedure takes a sample deep enough to reach the muscle, allowing doctors to clearly see the inflammation in the fascia that standard skin biopsies usually miss.
Why does my skin look like an orange peel?
In this condition, the immune system causes the fascia beneath your skin to severely thicken and harden. As this underlying tissue scars, it pulls on the surface skin above it, creating noticeable grooves along your veins or a dimpled, orange peel texture.
What are the initial treatments for Eosinophilic Fasciitis?
Early treatment is essential to stop inflammation and prevent permanent joint stiffness or freezing. Doctors typically begin treatment with high-dose corticosteroids, and they may add medications like methotrexate to help control the immune system's response.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my diagnosis been confirmed with a full-thickness 'en-bloc' biopsy that includes the fascia?
  2. 2.Given that EF is rare, how many patients with this condition have you or this clinic treated?
  3. 3.What is the goal of my initial treatment—are we starting with high-dose corticosteroids, or adding a second medication like methotrexate early on?
  4. 4.How will we monitor my progress? Will we use follow-up MRIs or blood tests to check my eosinophil levels?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Eosinophilic Fasciitis: New Developments and Future Directions.

    Huynh M, Bogdanski E, Fleshman T, et al.

    International journal of dermatology 2025; (64(8)):1356-1370 doi:10.1111/ijd.17809.

    PMID: 40452121
  2. 2

    Eosinophilic fasciitis following SARS-CoV-2 vaccination.

    Antuña VL, Puchades F, Tapial JM, et al.

    JAAD case reports 2023; (36()):11-14 doi:10.1016/j.jdcr.2022.11.038.

    PMID: 37131494
  3. 3

    Eosinophilic Fasciitis Without Skin Sclerosis.

    Komori K, Rokutanda R

    The Journal of rheumatology 2023; (50(7)):963-964 doi:10.3899/jrheum.220600.

    PMID: 36455945
  4. 4

    Groove Sign in Eosinophilic Fasciitis.

    Mourad AI, Lehman JS, Mydlarski PR

    Mayo Clinic proceedings 2021; (96(8)):2184 doi:10.1016/j.mayocp.2021.04.001.

    PMID: 34353471
  5. 5

    A difficult diagnosis of eosinophilic fasciitis: A case report.

    Mihailescu M, Abbas M

    SAGE open medical case reports 2024; (12()):2050313X241231384 doi:10.1177/2050313X241231384.

    PMID: 38665934
  6. 6

    Eosinophilic fasciitis with subjacent myositis.

    Whitlock JB, Dimberg EL, Selcen D, Rubin DI

    Muscle & nerve 2017; (56(3)):525-529 doi:10.1002/mus.25492.

    PMID: 27875630
  7. 7

    Eosinophilia complicated with venous thromboembolism: A case report.

    Su WQ, Fu YZ, Liu SY, et al.

    World journal of clinical cases 2022; (10(6)):1952-1960 doi:10.12998/wjcc.v10.i6.1952.

    PMID: 35317148
  8. 8

    Paraneoplastic eosinophilic fasciitis with generalized morphea and vitiligo in a patient working with organic solvents.

    Hanami Y, Ohtsuka M, Yamamoto T

    The Journal of dermatology 2016; (43(1)):67-8 doi:10.1111/1346-8138.13174.

    PMID: 26507670
  9. 9

    Eosinophilic Fasciitis: Current and Remaining Challenges.

    Mazilu D, Boltașiu Tătaru LA, Mardale DA, et al.

    International journal of molecular sciences 2023; (24(3)) doi:10.3390/ijms24031982.

    PMID: 36768300
  10. 10

    Eosinophilic Fasciitis and Smoldering Multiple Myeloma: An Exceptional Association in Young Adults.

    Jabbouri R, Bouanani N, Aniq Filali R, Aasfara J

    Cureus 2022; (14(4)):e23896 doi:10.7759/cureus.23896.

    PMID: 35530826
  11. 11

    Eosinophilic Fasciitis in a 78-Year-Old Man Following Pembrolizumab Treatment for Bladder Cancer.

    Oke I, Lenert A, Swick BL, Lenert P

    The American journal of case reports 2025; (26()):e948323 doi:10.12659/AJCR.948323.

    PMID: 41016045
  12. 12

    Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy.

    Boppana SH, Dulla NR, Beutler BD, et al.

    The American journal of case reports 2021; (22()):e932888 doi:10.12659/AJCR.932888.

    PMID: 34403405
  13. 13

    Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis.

    Jinnin M, Yamamoto T, Asano Y, et al.

    The Journal of dermatology 2018; (45(8)):881-890 doi:10.1111/1346-8138.14160.

    PMID: 29235676
  14. 14

    Diagnosis and treatment of eosinophilic fasciitis: Report of two cases.

    Song Y, Zhang N, Yu Y

    World journal of clinical cases 2021; (9(29)):8831-8838 doi:10.12998/wjcc.v9.i29.8831.

    PMID: 34734063
  15. 15

    The utility of rituximab in patients with eosinophilic fasciitis: case series from an Australian tertiary multidisciplinary clinic.

    Ali SB, Khoo T, Marshman G, et al.

    Clinical rheumatology 2026; (45(1)):559-572 doi:10.1007/s10067-025-07850-w.

    PMID: 41331198
  16. 16

    Immune checkpoint inhibitor-related eosinophilic fasciitis: 3 case reports with literature review.

    Biteau M, Sibaud V, Maria A, et al.

    La Revue de medecine interne 2025; (46(7)):377-385 doi:10.1016/j.revmed.2025.05.004.

    PMID: 40399177
  17. 17

    Diagnosis and treatment of early eosinophilic fasciitis: a case report.

    Ma J, Cai Y, Shao H, et al.

    Journal of medical case reports 2025; (19(1)):373 doi:10.1186/s13256-025-05440-7.

    PMID: 40731023
  18. 18

    Juvenile eosinophilic fasciitis: three case reports with review of the literature.

    Papa R, Nozza P, Granata C, et al.

    Clinical and experimental rheumatology 2016; (34(3)):527-30.

    PMID: 27268780

This page provides an educational overview of Eosinophilic Fasciitis (Shulman Syndrome). It is for informational purposes only and does not replace professional medical advice or a formal diagnosis from your specialist.

Get notified when new evidence is published on Eosinophilic fasciitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.